研究業績
2002年〜現在までの主な研究業績です。
| 2011年 | Ogawa R, Echizen H: Clinically significant drug interactions with antacids: an update. Drugs. 2011;71:1839-64. [PMID:21942976] |
|---|---|
| 小川竜一、陳惠一、緒方宏泰：科学的・合理的に薬物治療を実践するための文献評価の取り組み．アプライド・セラピューティクス．2011;2:36-60. | |
| 2010年 | Ogawa R, Echizen H: Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509-33. [PMID:20608754] |
| Ogawa R, Kishi R, Takagi A, Sakaue I, Takahashi H, Matsumoto N, Masuhara K, Nakazawa K, Kobayashi S, Miyake F, Echizen H: A novel microsatellite polymorphism of sodium channel beta1-subunit gene (SCN1B) may underlie abnormal cardiac excitation manifested by coved-type ST-elevation compatible with Brugada syndrome in Japanese. Int J Clin Pharmacol Ther. 2010;48:109-19. [PMID:20137763] | |
| 2009年 | Nakayama H, Echizen H, Gomi T, Shibuya Y, Nakamura Y, Nakano K, Arashi H, Ohnishi S, Tanaka M, Orii T: Urinary lipocalin-type prostaglandin D synthase: a potential marker for early gentamicin-induced renal damage? Ther Drug Monit. 2009;32:126-30. [PMID:19125150] |
| 2008年 | 神山尚子、小川竜一、浜田寛子、大野哲郎、浅野竜太、梅村純、吉田久博：冠動脈造影及び冠動脈形成術後の造影剤腎症に対するN-アセチルシステインの予防効果の検討．薬学雑誌. 2008;128:1333-9. [PMID:18758148] |
| Dohiguchi Y, Shiba S, Masuda Y, Kurihara Y, Hasegawa S, Echizen H: Bioequivalence studies between 0.5, 1, and 5 mg warfarin potassium tablets of new formula and those of standard formula. Jpn Pharmacol Ther. 2008;36:401-9. | |
| Nakayama H, Echizen H, Tanaka M, Sato M, Orii T: Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks. Ther Drug Monit. 2008;30:103-7. [PMID:18223471] | |
| 2007年 | Abe Y, Nanri Y, Oto H, Kitabayashi T, Watanabe S, Odajima Y, Itabashi K, Takahashi H, Echizen H: Effect of low-dose macrolide antibiotics on theophylline disposition in pediatric patients. 日本小児呼吸器疾患学会誌. 2007;18:7-13. |
| Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H: Meta-analysis of risk of malignancy with use of immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007;41:21-8. [PMID:17200426] | |
| Shibuya M, Okamoto H, Nozawa T, Utsumi J, Reddy VN, Echizen H, Tanaka Y, Iwata T: Proteomic and transcriptomic analyses of retinal pigment epithelial cells exposed to REF-1/TFPI-2. Invest Ophtalmol Vis Sci. 2007;48:516-21. [PMID:17251444] | |
| 佐藤(朝増)沙智子、三田充男、小川竜一、井坂眞人、齋藤政樹：経皮的冠動脈ステント留置術施行後の再狭窄に影響を及ぼす臨床的因子の検討．薬学雑誌. 2007;127:1309-15. [PMID:17666885] | |
| 2006年 | 田島満子、真鍋公二、小笠原芳宏、越前宏俊：ラロキシフェンによる閉経後骨粗鬆症に対する治療効果−滝山病院における１年間の調査−．日病薬誌. 2006;42:233-6. |
| 田島満子、両角 智、小笠原芳宏、越前宏俊：血液透析患者の高ホモシステイン血症の改善を目的とする葉酸サプリメント服用の試み．日病薬誌. 2006;42:511-6. | |
| Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie DM, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H: Different contribution of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasian and African Americans. Pharmacogenet Genomics. 2006;16:101-10. [PMID:16424822] | |
| Ogawa R, Kishi R, Mihara K, Takahashi H, Takagi A, Matsumoto N, Masuhara K, Nakazawa K, Miyake F, Kobayashi S, Echizen H: Population Pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias. J Clin Pharmacol. 2006;46:59-68. [PMID:16397285] | |
| 2005年 | Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, Takagi T: In vivo metabolic activity and genetic polymorphism of CYP2C19 and CYP3A in chronic liver disease. J Clin Pharmacol. 2005;45:1221-9. [PMID:16239354] |
| 2004年 | Ohno K, Masunaga Y, Ogawa R, Hashiguchi M, Ogata H: A systematic review of the clinical effectiveness of azathioprine in patients with ulcerative colitis. Yakugaku Zasshi. 2004;124:555-60. [PMID:15297725] |
| 岸 良示、中沢 潔、高木明彦、原田智雄、三宅良彦、小川竜一、越前宏俊、松本直樹、小林真一：ナトリウムチャネルβ-1サブユニット遺伝子の遺伝子多型が見られたBrugada症候群の1家系．心臓. 2004;36 Suppl 4:163-7. | |
| 岸 良示、中沢 潔、小川竜一、松本直樹、高木明彦、長田圭三、桜井庸晴、宮津 修、渡邉義之、松田央郎、村野浩太郎、麻生健太郎、原田智雄、三宅良彦：多数の突然死の家族歴を有する特発性肥大型心筋症とBrugada症候群の合併家系．心臓. 2004;36 Suppl 3:24-8. | |
| Takahashi H, Wilkinson GR, Padrini R, Echizen H: CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther. 2004;75:376-80. [PMID:15116049] | |
| Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H: 5´-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in Caucasian and Japanese patients. Blood. 2004;103:3055-7. [PMID:15070684] | |
| Yamaguchi T, Ida T, Hiraga M, Oishi K, Uchida MK, Echizen H: Effects of angiotensin II receptor blockers, angiotensin converting enzyme Inhibitors, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase inhibitors, amlodipine and epalrestat on cultured basilar artery smooth muscle cell proliferation. J Pharm Soc Jpn. 2004;124:159-63. [PMID:15049134] | |
| Yamaguchi T, Ida T, Kobayashi T, Hiraga M, Oishi K, Uchida MK, Echizen H: Alterations of antiproliferative effects of serum obtained from patients with acute cerebral infarction treated with a radical scavenger, edaravone, with or without amlodipine using an in vitro cultured basilar artery smooth muscle cells. J Pharm Soc Jpn. 2004;124,25-30. [PMID:14768352] | |
| 2003年 | Yamaguchi T, Oishi K, Uchida M, Echzien H: Edaravone, a radical scavenger, may enhance or produce antiproliferative effects of fluvastatin, amlodipine, ozagrel, GF109203 and Y27632 on cultured basilar artery smooth muscle cells. Biol Pharm Bull. 2003;26:1706-10. [PMID:14646175] |
| Ohno K, Miyazawa S, Hashiguchi M, Unemoto T, Itoh A, Echizen H, Rikihisa T, Ogata H, Murata M: Establishing a comprehensive questionnaire for detecting drug-induced extrapyramidal symptoms. Yakugaku Zasshi. 2003;123:881-6. [PMID:14577334] | |
| Saruwatari J, Nakagawa K, Shindo J, Nachi S, Echizen H, Ishizaki T: The in-vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man. J Pharm Pharmacol. 2003;55:1553-9. [PMID:14713367] | |
| Takahashi H, Echizen H: Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmcogenomics J. 2003;3:202-14. [PMID:12931134] | |
| Shibuya M, Echizen H, Kubo S, Tamura N, Suzuki K, Ushiama H, Ohnishi A: Reduced urinary 6beta-hydroxycortisol to cortisol ratios in patients with liver cirrhosis. Hepatology Res. 2003;26:28-33. [PMID:12787801] | |
| Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H: Population differences in (S)-warfarin metabolism between CYP2C9 genotype-matched Caucasians and Japanese patients. Clin Pharmacol Ther. 2003;73:253-63. [PMID:12621390] | |
| 2002年 | 小川竜一、岸良示、高木昭彦、松本直樹、坂上逸孝、三原潔、高橋晴美、増原慶壮、緒方宏泰、力久忠昭、越前宏俊、中沢潔、小林真一、三宅良彦：塩酸ピルジカイニドの薬理効果における患者間変動要因の検討．臨床薬理. 2002;33:347S-8S. |
| 宇治田和子、大野恵子、橋口正行、越前宏俊、力久忠昭、緒方宏泰：市中病院における高脂血症に対する薬物治療の現状と問題点の検討．薬学雑誌. 2002;122:499-506. [PMID:12136647] | |
| Kanamori M, Takahashi H, Echizen H: Developmental changes in the liver weight-and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. Int J Clin Pharmacol Ther. 2002;40:485-92. [PMID:12698985] | |
| Ohkawa K, Hashiguchi M, Ohno K, Kiuchi C, Takahashi S, Kondo S, Echizen H, Ogata H: Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther. 2002;72:220-6. [PMID:12189369] | |
| Ushiama H, Echizen H, Nachi S, Ohnishi A: Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther. 2002;72:33-43. [PMID:12152002] | |
| Takahashi M, Echizen H, Takahashi K, Shimada S, Aoyama N, Izumi T: Extremely prolonged elimination of cibenzoline at toxic plasma concentrations in patients with renal impairments. Ther Drug Monit. 2002;24:492-6. [PMID:12142632] | |
| Kadota K, Kamata K, Kobayashi Y, Kagaya H, Shimada S, Yoshimoto-Furuie K, Echizen H: Nomogram for individualizing supplementary iron doses during erythropoietin therapy in haemodialysis patients. J Clin Pharm Ther. 2002;27:111-9. [PMID:11975695] | |
| Saima S, Furuie K, Yoshimoto H, Fukuda J, Hayashi T, Echizen H: The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. Br J Clin Pharmacol. 2002;53:203-6. [PMID:11851646] |